LaQuita Jones Lab

Publications

Jones, L; Khadaroo, A; Tiwari, R; Choi, K; Adam, M; Wunderlich, M; Stillwell, C; Sexton, C; Seibel, W; Tawa, G; Hoyt, S; Thomas, C; Starczynowski, D. FLT3-F691L confers kinase-independent resistance via Grb2-dependent MAPK signaling in AML. Blood. 2025; 146(Supplement 1):5049-5049.

Hoyt, SB; Finocchio, CJ; Croll, E; Tawa, GJ; Zhang, M; Wang, J; Li, H; Ma, L; Li, K; Zhang, X; Culver-Cochran, AE; Rosenbaum, JS; Starczynowski, DT; Thomas, CJ. IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia. ACS Medicinal Chemistry Letters. 2025; 16(5):887-895.

Hoyt, SB; Finocchio, CJ; Croll, E; Tawa, GJ; Li, H; Ma, L; Li, K; Liu, L; Li, R; Zhang, X; Culver-Cochran, AE; Rosenbaum, JS; Starczynowski, DT; Thomas, CJ. Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia. ACS Medicinal Chemistry Letters. 2024; 15(11):1843-1851.

Leblanc, FR; Breese, EH; Burns, KC; Chang, EK; Jones, LM; Lee, L; Mizukawa, B; Norris, RE; O'brien, MM; Phillips, CL; Perentesis, JP; Rubinstein, J; Pommert, L. Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. British Journal of Haematology. 2024; 205(3):1055-1066.

Jones, LM; Starczynowski, DT. IKAROS and MENIN in synergy in AML. Nature Cancer. 2022; 3(5):528-529.

Jones, LM; Tarlock, K; Cooper, T. Targeted Therapy in Pediatric AML: An Evolving Landscape. Paediatric Drugs. 2021; 23(5):485-497.

Jones, LM; Regan, C; Wolf, K; Bryant, J; Rakowsky, A; Pe, M; Snyder, DA. Effect of osteopathic manipulative treatment on pulmonary function testing in children with asthma. Journal of Osteopathic Medicine. 2021; 121(6):589-596.

Jones, L; Melgar, K; Hoyt, S; Wunderlich, M; O’Brien, E; Perentesis, J; Thomas, C; Starczynowski, D. 81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML. Journal of Clinical and Translational Science. 2021; 5(Suppl 1):100-100.

Jones, LM; O'brien, MM; Breese, EH; Absalon, M; Burns, KC; Grimley, M; Mizukawa, B; Lee, LH; Perentesis, JP; Phillips, CL. Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML. Journal of Clinical Oncology. 2020; 38(15_suppl):e22502-e22502.

Jones, LM; Melgar, K; Bolanos, L; Hueneman, K; Walker, MM; Jiang, J-K; Wilson, KM; Zhang, X; Shen, J; Jiang, F; O'brien, E; Perentesis, JP; Starczynowski, DT; Thomas, CJ. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. Journal of Clinical Investigation. 2020; 130(4):2017-2023.